Lilly’s lebrikizumab yielded durable skin clearance in Phase 3 atopic dermatitis studies

Eli Lilly and Company’s (NYSE:LLY) Phase 3 monotherapy ADvocate trials in atopic dermatitis (AD) found that the investigational interleukin 13 inhibitor lebrikizumab supported durable skin clearance and reduced itching in a subset of patients with atopic dermatitis.

The Indianapolis–based company defined responders as those with at least 75% improvement in the Eczema Area and Severity Index from baseline (EASI-75) or an Investigator Global Assessment of 0 or 1 (“clear” or “almost clear”) with a 2-point improvement at week 16 without rescue medication. The clinical trial re-randomized responders to receive lebrikizumab 250 mg every two weeks or four weeks or a placebo for 36 more weeks.

Lebrikizumab performed similarly in responders when dosed at a two- or four-week interval after week 16.

“Despite available treatment options, many patients with atopic dermatitis experience distressing symptoms every day over the course…

Read more
  • 0

Lilly’s lebrikizumab with topical corticosteroids improved atopic dermatitis in the study

Eli Lilly (NYSE:LLY) has announced promising results from a Phase 3 study of patients with moderate-to-severe atopic dermatitis (AD).

At 16 weeks, 70% of patients with moderate-to-severe atopic dermatitis (AD) taking both lebrikizumab and standard-of-care topical corticosteroids (TCS) achieved at least 75% improvement in overall disease severity (EASI-75*) in the ADhere trial.

The company made the announcement at the fourth annual Revolutionizing Atopic Dermatitis (RAD) Conference.

The combination of lebrikizumab, an experimental investigational interleukin (IL)-13 inhibitor, and topical corticosteroids also resulted in itch symptoms, sleep and quality of life compared with placebo and topical steroids.

“Today’s ADhere data, together with results from the ADvocate monotherapy studies, demonstrate the potential for lebrikizumab to reduce disease burden and provide relief for people with uncontrolled atopic dermatitis when used either al…

Read more
  • 0